The EPA health risk assessment of methylcyclopentadienyl manganese tricarbonyl (MMT)

被引:39
作者
Davis, JM [1 ]
Jarabek, AM
Mage, DT
Graham, JA
机构
[1] US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA
[2] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA
关键词
MMT; manganese health risks; inhalation reference concentration; benchmark dose; Bayesian analyses; personal exposure distribution;
D O I
10.1111/j.1539-6924.1998.tb00916.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This paper describes the U.S. Environmental Protection Agency's assessment of potential health risks associated with the possible widespread use of a manganese (Mn)-based fuel additive, methylcyclopentadienyl manganese tricarbonyl (MMT). This assessment was significant in several respects and may be instructive in identifying certain methodological issues of general relevance to risk assessment. A major feature of the inhalation health risk assessment was the derivation of Mn inhalation reference concentration (RfC) estimates using various statistical approaches, including benchmark dose and Bayesian analyses. The exposure assessment component used data from the Particle Total Exposure Assessment Methodology (PTEAM) study and other sources to estimate personal exposure levels of particulate Mn attributable to the permitted use of MMT in leaded gasoline in Riverside, CA, at the time of the PTEAM study; on this basis it was then possible to predict a distribution of possible future exposure levels associated with the use of MMT in all unleaded gasoline. Qualitative as well as quantitative aspects of the risk characterization are summarized, along with inherent uncertainties due to data limitations.
引用
收藏
页码:57 / 70
页数:14
相关论文
共 45 条
[1]   DOSE-RESPONSE ASSESSMENT FOR DEVELOPMENTAL TOXICITY .2. COMPARISON OF GENERIC BENCHMARK DOSE ESTIMATES WITH NO OBSERVED ADVERSE EFFECT LEVELS [J].
ALLEN, BC ;
KAVLOCK, RJ ;
KIMMEL, CA ;
FAUSTMAN, EM .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1994, 23 (04) :487-495
[2]   BENCHMARK DOSE WORKSHOP - CRITERIA FOR USE OF A BENCHMARK DOSE TO ESTIMATE A REFERENCE DOSE [J].
BARNES, DG ;
DASTON, GP ;
EVANS, JS ;
JARABEK, AM ;
KAVLOCK, RJ ;
KIMMEL, CA ;
PARK, C ;
SPITZER, HL .
REGULATORY TOXICOLOGY AND PHARMACOLOGY, 1995, 21 (02) :296-306
[3]  
CLAYTON CA, 1993, J EXPO ANAL ENV EPID, V3, P227
[4]   CHRONIC MANGANESE POISONING - CLEARANCE OF TISSUE MANGANESE CONCENTRATIONS WITH PERSISTENCE OF NEUROLOGICAL PICTURE [J].
COTZIAS, GC ;
HORIUCHI, K ;
FUENZALIDA, S ;
MENA, I .
NEUROLOGY, 1968, 18 (04) :376-+
[5]   INTERACTIONS BETWEEN MANGANESE AND BRAIN DOPAMINE [J].
COTZIAS, GC ;
MILLER, ST ;
PAPAVASILIOU, PS ;
TANG, LC .
MEDICAL CLINICS OF NORTH AMERICA, 1976, 60 (04) :729-738
[6]   A NEW METHOD FOR DETERMINING ALLOWABLE DAILY INTAKES [J].
CRUMP, KS .
FUNDAMENTAL AND APPLIED TOXICOLOGY, 1984, 4 (05) :854-871
[7]  
DAVIS JM, 1993, NEUROTOXICOLOGY, V14, P15
[8]  
DAVIS JM, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P150
[9]   THE EFFECT OF CHRONIC MANGANESE ADMINISTRATION ON SOME NEUROCHEMICAL AND PHYSIOLOGICAL VARIABLES IN NEONATAL RATS [J].
DESKIN, R ;
BURSIAN, SJ ;
EDENS, FW .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1981, 12 (04) :279-280
[10]   MANGANESE NEUROTOXICITY - A MODEL FOR FREE-RADICAL MEDIATED NEURODEGENERATION [J].
DONALDSON, J ;
MCGREGOR, D ;
LABELLA, F .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1982, 60 (11) :1398-1405